“We continue to accumulate important RSV data and expansion of how the -- this important vaccine can be used. So you should expect this first half of the year, likely Q2, that we share more from our clinical trials, including full second season but also expansion in traditional age groups.”

In context

“eases, immuno-inflammation antivirals are the ones that we are continuing to invest in. Operator: Next, we have Kerry Holford with Berenberg. Kerry Holford : Just a couple of pipeline questions for me, please. Firstly, on RSV. Can we expect you to announce the date for Abrysvo following that third season in Q2? And then also on the two Phase 3 starts, you've highlighted today B6A in lung and CDK4 in breast. When can we expect Phase 3 data readouts for these two products? Albert Bourla: I'm not sure -- what was your question on RSV? Kerry Holford : To understand when are you going to publish the data from the following the third season, third winter season of RSV? Albert Bourla: Yes. Yes, I got it. Thank you. Why don't you take that, Mikael, on the Abrysvo? And then, Chris. Mikael Dolsten: We continue to accumulate important RSV data and expansion of how the -- this important vaccine can be used. So you should expect this first half of the year, likely Q2, that we share more from our clinical trials, including full second season but also expansion in traditional age groups, as you can know, on clintrial.gov, we have active trials, and we think that will very nicely allow high-risk groups across a large age span to be addressed. Albert Bourla: Thank you, Mikael. And then, Chris? Chris Boshoff: Thank you very much for the question. So the immediate readouts for this year, second half 2024 will be the [indiscernible] in second-line hormone receptor positive metastatic breast cancer, the VERITAC-2 study, also second half 2024. We expect to anticipate results from BREAKWATER, very important indication, up to 12% of colorectal cancer with BRAFTOVI in first-line BRAF CRC. The new study starting right now is CDK4, B6A and dasitumab in Phase 3 programs and then also later this year for ECH2. Those will appear in clinicaltrials.gov and primary completion dates beyond”